New study: Only reliable rapid corona tests make sense
mehr
Storys zum Thema Gesundheit / Medizin
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
nal von minden plans to produce 80 million rapid corona tests per month
mehr- 2
German MECOTEC Group launches one-stop-solution for deep-freeze, transport, storage and distribution for COVID-19-Vaccines with its first Mobile Hybrid Container
mehr Swiss Rockets AG announces the founding of ROCKETVAX for the development of a next-generation SARS-CoV-2 vaccine
mehrEuropean Commission launches EUR 8 million Next-Generation IoT environments project amid Covid-19 pandemic
mehrNew: Combined rapid test for Covid-19 and influenza
mehrEvoBiotiX collaborates with Boehringer Ingelheim and the University of Salzburg on naturally derived Extracellular Vesicles (EVs)
Salzburg/Melide(CH) (ots) - Swiss Biotech EvoBiotiX SA today announced a multi-year collaboration with Boehringer Ingelheim in the field of naturally derived EVs. A significant part of this program will fund research of the drug delivery potential of naturally derived EVs in the group of Prof. Meisner-Kober at the ...
mehrNew Covid-19 antigen test: Fast and reliable results in just 15 minutes
mehrThe mobility specialist REHASENSE cooperates with Krzysztof Pietrasik
mehrNTT DATA Business Solutions AG
2it.lifesciences for plasma: Accelerator for the human blood plasma manufacturing industry
mehrRevolutionary face mask can prevent cross-contamination
mehrFinnish coronavirus tracing app Koronavilkku reaches 2 million downloads
Helsinki (ots) - The Finnish Koronavilkku ('Corona Blinker') application, which helps to break chains of coronavirus infection, has already been downloaded over 2 million times. The milestone of 2 million downloads - 37 % of the population - was reached two weeks after the application became available for download in app stores. 'We all now have a genuine opportunity ...
mehrHARTMANN launches Mission: Infection Prevention - how prevention is contagious
mehrUMIT - The Health & Life Sciences University
University UMIT TIROL publishes the first population model to evaluate benefits and harms of universal salt iodization
Hall in Tirol (ots) - An article recently published by Schaffner and colleagues in the medical journal "Thyroid" summarizes the results of a decision-analytic population modeling study evaluating the benefits and harms of universal salt iodization. Iodine is a micronutrient that is essential for the production of ...
mehrSysmex Inostics' Liquid Biopsy Testing Benefits Metastatic Pancreatic Cancer Patient Management
Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating cell-free tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study investigating the utility of cfDNA-based markers using the highly sensitive OncoBEAM RAS assay, an enhanced ...
mehrKORSCH Introduces Next-Generation Mid-Range Tablet Press
mehrSysmex Inostics' OncoBEAMTM RAS CRC testing supports clinical outcome improvements for metastatic colorectal cancer patients rechallenged with anti-EGFR therapy
Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating RAS mutation status in circulating tumor DNA (ctDNA) of colorectal cancer (CRC) patients undergoing anti-EGFR ...
mehrEffectiveness and efficiency of targeted intra-operative single dose radiotherapy for breast cancer patients confirmed
Jena, Germany (ots) - New long-term results from the international TARGIT-A breast cancer study, based on ZEISS technology, have been published [1] Use of targeted intra-operative radiotherapy (TARGIT), as a single dose - with ZEISS INTRABEAM - directly after removal of a tumor, confirmed as non-inferior, when ...
mehrSysmex-Inostics Colorectal Cancer Blood-Based OncoBEAMTM RAS CE-IVD Test Shows Concordance with Standard of Care Tissue-Based RAS Testing
Baltimore, Maryland (ots) - Sysmex-Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating the performance of plasma RAS mutation testing with OncoBEAM RAS CRC as compared to standard of care ...
mehrWe+Care: EUR1.5 million to increase the quality at the end of life
mehrDr. Rath Education Services BV
Micronutrient Combination Suppresses Cell 'Entry Door' For Coronavirus
mehrIgNova files patent application on antibody against COVID-19
Visbek, Germany (ots) - IgNova announced today that it has filed a patent application covering the use of passive immunization to control SARS-CoV-2 infection in humans. IgNova, a biopharmaceutical R&D start up, researches technology based on specific egg immunoglobulins (IgY). The patented IgY binds the spike protein of SARS-CoV-2, neutralizing the virus when it enters the mouth or nose and, therefore, inhibiting the ...
mehrHAPA pharm receives GMP certification / Quality assured medical cannabis products
Dortmund (ots) - HAPA pharm ("HAPA" or the "Company") operates production facilities in North Macedonia to grow and process medical cannabis for the sale of pharmaceutical cannabis flos and extracts. On May 1st 2020, the Company has successfully received GMP (Good Manufacturing Practice) approval for both facilities. This milestone demonstrates HAPA's commitment ...
mehrMediaform Informationssysteme GmbH
The Mediaform group of companies is working towards the launch of an EU Health Passport
mehr- 2
Innovation: Intelligent bacteria demonstrate high efficacy in the treatment of widespread disease irritable bowel syndrome with typical symptoms of recurrent diarrhoea, abdominal pain, bloating and constipation
mehr Eleva's drug candidate to be examined for use in Covid-19 treatment
Freiburg (ots) - Eleva, a manufacturer of superior biologics, is exploring the potential of one of its drug candidates for first-in-line therapy of Covid-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of Covid-19. Eleva has developed factor H previously for a different indication and taken it through ...
mehrWSSCC Names New Executive Director
mehr- 2
FLUXERGY ANNOUNCES $30 MILLION TO EXPAND MANUFACTURING CAPACITY OF ITS ONE-HOUR POINT-OF-CARE DIAGNOSTIC TESTING SYSTEM IN RESPONSE TO COVID-19
mehr ATMOS MedizinTechnik GmbH & Co. KG
2Face protection against droplet infection from ATMOS
mehr- 2
Fielmann starts producing protective glasses
mehr
Vorherige234567891011Nächste